acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cytokinetics to Announce First Quarter Results on May 6, 2014 (Next Tuesday):
http://finance.yahoo.com/news/cytokinetics-announce-first-quarter-results-204101134.html
Buy a few shares before the conference call.
Needham: $15.00 Price Target - Buy Rating
p.s. Shorts need million of shares to cover.
Market cap of $150M is much too low. Added a few more shares today.
Fortunately I didn't own it before Friday's sell off.
I'll add a few more shares if it drops much further.
GLTY
Expecting a nice bounce before Wednesday's webcast.
GLTY.
Needham places $15.00 price target on $CYTK. Buy rating.
http://zolmax.com/investing/cytokinetics-price-target-cut-to-15-00-by-analysts-at-needham-company-llc-cytk/253238/
p.s. Buy a few shares before tomorrow's presentation and Wednesday's webcast.
Cytokinectics As An Amgen Takeover Target Would Make Perfect Sense
Amgen Inc. moved into Q2 2014 with $22.81 billion in cash and equivalents on its balance sheet.In the last year Amgen Inc. invested a reported $9.69 billion in company mergers and acquisitions.
Amgen is working with Cytokinetics on omecamtiv mecarbil, a drug for the treatment of heart failure, a chronic condition responsible for the hospitalization of more than 1 million people in the U.S. every year.
Omecamtiv mecarbil is currently in phase 2 trials seeking to demonstrate that the drug can boost heart muscle function and reduce hospital readmission.
Amgen initially signed on for an option to work with Cytokinetics on the drug in 2006 when it paid the company $75 million upfront. Amgen executed that option in 2009, handing over another $50 million and taking on responsibility for development and commercialization in exchange for global rights to omecamtiv.
Overall, Cytokinetics may receive up to $600 million in milestones from Amgen and double digit royalties.
With Cytokinetics' market cap currently in the $160M range it seems that it makes perfect sense for Amgen to make a bid for the company.
The corporate offices for the two companies make them neighbors already.
Stranger things have happened.
Just saying!!!
I don't think Gerald would sell the company for $200M so obviously your suggestion that "big pharma" could buy it for $52M currently is a bit foolish.
There are any number of realistic catalysts that could easily double or triple the share price at any time.
It's amazing that individuals that have no position in a stock have nothing better to do than drop in occasionally with their negative comments.
99% of the time at some price everyone is a buyer and at some price everyone is a seller.
Twitter: @AmarantusBio .... 9.926 followers
p.s. Everyone wants a lower price.
Over $1,000,000,000 in milestone payments plus royalties.
Nice carrot for the shareholders.
Expecting the share price to be back above $7.00 by June 1. Shorts need millions of shares here.
Collaborations under way:
Tirasemtiv was the only one of Cytokinetics' three drugs under development to lack a well-heeled partner. The other two drugs in Cytokinetics' pipeline are being co-developed with either Amgen (NASDAQ: AMGN ) or Japan's Astellas (NASDAQOTH: ALPMY ) .
Amgen is working with Cytokinetics on omecamtiv mecarbil, a drug for the treatment of heart failure, a chronic condition responsible for the hospitalization of more than 1 million people in the U.S. every year.
Omecamtiv mecarbil is currently in phase 2 trials seeking to demonstrate that the drug can boost heart muscle function and reduce hospital readmission.
Amgen initially signed on for an option to work with Cytokinetics on the drug in 2006 when it paid the company $75 million upfront. Amgen executed that option in 2009, handing over another $50 million and taking on responsibility for development and commercialization in exchange for global rights to omecamtiv.
Overall, Cytokinetics may receive up to $600 million in milestones from Amgen and double digit royalties if the drug ever reaches the market.
More recently, Astellas inked a collaboration deal with Cytokinetics last summer for the development of CK-107.
Under the collaboration deal with Astellas, Cytokinetics can receive up to $40 million in payments over a two year period. If Astellas advances the drug further through trials and eventually toward commercialization, Cytokinetics could receive up to $450 million in milestones.
Interesting week ahead. Shorts need millions of shares to cover. It's one thing to short with the "herd". I expect the "herd" will be moving on to greener pastures.
Have a great weekend!!!
The traders will move on to the next volatile opportunity. It bounced off of the 52 week low. I think it will be in the $5.50 range and trending higher by Wednesday's webcast.
Shorting at the bottom is just as bad as buying at the top.
GLTY
Tuesday's presentation and Wednesday's webcast should add clarification to the situation according to Ms. Goldstein in I.R.
Stay tuned for news.
p.s. I think the current share price offers more upside than downside. The shorts need millions of shares to cover and any hint of positive news will act as a catalyst to start the covering frenzy.
At such a low share price a takeover play by Amgen could be a reasonable outcome. It would benefit all parties. $7.00/share?
Nice addition to Amgen's pipeline.
Reasonable expectations. Sooner would be better.
I just finished listening to the conference call a second time. There's a substantial amount of information disclosed there.
It still amazes me that the share price isn't above .20 currently.
I'll buy them for .06.
Put in a limit sell order (a.o.n.) for 1,000,000 shares at .06 and I'll buy them.
Get it over with and move on.
Thanks in advance.
Twitter: @AmarantusBio .... 9,925 followers
Very informative call.
It's obvious that Gerald has a long term plan to make the company a success and he's assembling a team of professionals to implement the plan.
Exciting times ahead for the shareholders.
Twitter: @AmatantusBio .... 9,925 followers.
It's not indicating anything: good, bad, or ugly.
Traders are treading water waiting to see what Gerald has to say.
Twitter: @AmarantusBio .... 9,925 followers.
Note to Desolation Row: "No one cares."
Twitter: @AmarantusBio .... 9,224 followers.
p.s. Check the three month chart. Looks like a bottom to me.
http://finance.yahoo.com/q/bc?s=AMBS&t=3m&l=on&z=l&q=l&c=
I think Thursday's conference call is going to be a "blockbuster" for the shareholders.
I wouldn't be surprised if the share price is above .10 at the open on Friday.
"Patience is a virtue."
Gerald's "Proactive" Tweet:
"I have received a number of questions, so I will address: $AMBS is not a party to any court case and LymPro is on track for later this year."
Twitter: @AmarantusBio .... 9,915 followers. 10,000 soon!!!
p.s. Ignore the "negative noise". Everyone wants cheaper shares.
I think this will be a very worthwhile conference call that will garner some specific responses from Gerald with more defined time frames.
If it is as positive as I think it could be I think the share will open above .10 on Friday and move higher.
The shareholders are due for a substantial move higher in the share price after Gerald makes a presentation. Time to break the pattern.
Twitter: @AmarantusBio .... 9,911 followers.
Why ask me?
I don't "follow" the individual. I just "blocked" him.
He's obviously someone who needs or wants cheaper $AMBS shares.
Twitter: @AmarantusBio .... 9,911 followers.
p.s. Are you calling to ask Gerald some provocative questions on Thursday? Great opportunity for you to gain some guidance.
It's only "unicorns in the clouds" until it's actually "horses on the ground".
"Patience is a virtue."
I added a few shares today. It's still oversold and undervalued relative to reasonable potential upside.
Twitter: @AmarantusBio .... 9,911 followers. Expecting to go over 10,000 by Friday. Remember to "retweet" the company's tweets.
Isn't it about time that the share price actually moves higher after a conference call or presentation?
Sooner or later the odds favor a move higher the following trading session.
Just saying!!!
Twitter: @AmarantusBio .... 9,910 followers.
p.s. Jason Napadano will be in attendance.
Don't know why anyone would sell before Thursday's shareholder's conference call.
The 10-K "crisis" is behind us. No harm no foul.
Overdue for positive news.
Just saying!!!
Twitter: @AmarantusBio .... 9,910 followers. Remember to "retweet" the company's tweets.
It could change at any time with a development partnership for one of the orphan indications for MANF or with a marketing partnership for LymPro.
The potential number of realistic catalysts that could occur at any time is what makes owning $AMBS shares so much fun.
Twitter: @AmarantusBio .... 9,907 followers.
Remember Gerald's post: "If you can't stand the heat get out of the kitchen."
I assume he believes that to be applicable to any of the $AMBS shareholders.
The 10-K didn't reveal anything regarding dilution that wasn't anticipated. Actually that's a good thing.
Let's see if any news comes out before Thursday's conference call and what Gerald has to say on Thursday about the LymPro launch, the up-listing, and potential partnerships.
"Patience is a virtue."
Twitter: @AmarantusBio .... 9,907 followers.
If your initial time frame was January/February and it didn't happen that would lead me to conclude that the probability of good news has increased substantially considering the additional time that has elapsed.
This is still one p.r. away from the share price doubling or tripling. Not if but when.
Don't be on the sidelines hoping for a better price when it happens.
Twitter: @AmarantusBio .... 9,906 followers.
It would be great to get some positive news before Thursday to create some upward momentum leading into the shareholder's conference call.
Just saying!!!
Twitter: @AmarantusBio .... 9,906 followers.
If the 10-K is filed on Monday I wouldn't be surprised if we get a new Chairman's blog from Gerald on Tuesday.
Time to go enjoy Easter Sunday.
Have a great day!!!
I don't think the share price will go below .06 unless the 10-K reveals dilution substantially beyond the 800M that is currently expected and is delayed beyond Monday.
The investors that converted the warrants at .06 to 50M shares have a vested interest in keeping the share price above .06. The share price dropped the last three trading sessions on relatively low volume. Also we are overdue for positive news. There hasn't been a "tweet" from @AmarantusBio since April 9 which is very unusual.
However, if by chance the new C.F.O. and accounting firm uncovered irregularities that substantially impact the company's financial situation then all bets are off especially if the new trading symbol becomes AMBSE next week. If that were to occur then .04 could happen. Remember .04 is the bottom price that LPC is obligated to purchase shares from the company.
I tried calling the company last Thursday and Friday and no one answered. I e-mailed Aimee several times and got no reply. It appears that Gerald has also gone silent on Twitter but that may well be on the advice of legal counsel.
Let's all enjoy Easter with our families and hope that tomorrow we'll have some well deserved answers. It's not nice to keep the shareholders and the market in the dark.
Twitter: @AmarantusBio .... 9.904 followers
All IMHO.
A good place to start to conduct your due diligence:
http://cavendishglobal.com/index.html
Twitter: @AmarantusBio .... 9,904 followers.
He wasn't paid $500,000 per year.
Please explain where you got that figure. You may also want to explain how stock options are valued and how and when they are executed and when they become more valuable.
Just saying!!!
If Mr. Farrell needed a few extra days to put the company's financial reporting as it should be then so be it. Time to get the 10-K filed and in the past.
Mr. Farrell's background:
Mr. Farrell served as Chief Financial Officer of Titan Pharmaceuticals from 1996 to 2008, and as President and CEO from 2008 to 2010. During his tenure at Titan Mr. Farrell was responsible for all SEC filings, fund raising, financial and tax planning strategies, mergers & acquisitions, corporate partnerships, licensing transactions and financial operations, where he raised over $390M via public equity and non-dilutive financings, including seven corporate partnerships.
Mr. Farrell most recently served as CFO at Sanovas, Inc. Mr. Farrell previously served as CFO, Corporate Group Vice President and General Counsel at Fresenius USA and Fresenius Medical Care where he completed 6 corporate partnership and M&A transactions totaling over $4B. Mr. Farrell also previously served as the CFO for the Institute for One World Health in San Francisco and currently serves on the Board of Directors of Prime Genomics, Inc. Mr. Farrell holds a J.D. from the University of California's Hastings School of Law.
My comment: If anyone wants to sell shares for less than .07 there will be plenty of buyers. I guarantee it.
Your insights are appreciated.
Have a great day!!!
Twitter: @AmarantusBio .... 9,901 followers.
Remember the new C.F.O. has been with the company a little over two weeks.
Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
SAN FRANCISCO, April 1, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the appointment of Mr. Robert Farrell, J.D. as Chief Financial Officer. Mr. Farrell brings over 20 years of healthcare, public company and CFO experience to Amarantus. Mr. Marc Faerber will continue with Amarantus in his new role as Corporate Controller and Vice President of Financial Operations.
"Amarantus is very well positioned to generate significant shareholder value through the further development and commercialization of its key assets in the months and years ahead," said Mr. Farrell, Amarantus' newly appointed Chief Financial Officer. "I am pleased to be joining now at this critical juncture as the Company prepares to uplist its common shares to a national stock exchange in 2014 as we commercialize LymPro, initiate a Phase 2B clinical trial for Eltoprazine in Parkinson's disease and prepare the MANF Program for an orphan drug designation submission. We expect 2014 to be a transformative year for Amarantus as we lay the groundwork for long-term shareholder value creation."
Mr. Farrell served as Chief Financial Officer of Titan Pharmaceuticals from 1996 to 2008, and as President and CEO from 2008 to 2010. During his tenure at Titan Mr. Farrell was responsible for all SEC filings, fund raising, financial and tax planning strategies, mergers & acquisitions, corporate partnerships, licensing transactions and financial operations, where he raised over $390M via public equity and non-dilutive financings, including seven corporate partnerships. Mr. Farrell most recently served as CFO at Sanovas, Inc. Mr. Farrell previously served as CFO, Corporate Group Vice President and General Counsel at Fresenius USA and Fresenius Medical Care where he completed 6 corporate partnership and M&A transactions totaling over $4B. Mr. Farrell also previously served as the CFO for the Institute for One World Health in San Francisco and currently serves on the Board of Directors of Prime Genomics, Inc. Mr. Farrell holds a J.D. from the University of California's Hastings School of Law.
"We are extremely pleased to add Robert Farrell to our team as we begin to build momentum towards uplisting our common shares on a national stock exchange in 2014," said Gerald E. Commissiong, President & CEO of Amarantus. "I am excited to work closely with Bob as we move our products ahead in order to maximize the value of our equity and mitigate risks going forward. Bob will bring invaluable experience to our team as we continue to build Amarantus into a world class company dedicated to bringing meaningful solutions to patients."
I think if I were the company's legal counsel I would advise Gerald not to make any comments in the social media about the 10-K being late or about why it is late.
I would tell Gerald to get it filed and move on. The delay can't be undone so why focus on it.
Lesson learned.
Twitter: @AmarantusBio .... 9,901 followers
It will be nice to have a three day break from the trials and tribulations associated with Amarantus.
Best wishes for a "Happy Easter" to everyone.
Twitter: @AmarantusBio .... 9,901 followers. Closing in on 10,000.
p.s. Buy a few shares before the close. You never know when that "one" p.r. will be released.
What a difference a few weeks make.
How did filing the 10-K a few days late impact all the great things that were supposebly in the works?
Now the sky is falling.
I now put you in the same class as WatsonHelper.
Twitter: @AmarantusBio .... 9,899 followers
p.s. How many shares have you or your group sold in the last two weeks?
Let's all look forward to next week with the 10-K filed and some positive press releases to get the share price headed up.
There are still too many potential catalysts that could double/triple the share price at any time to not be optimistic about the company's future.
Napadano says it's still worth .24
Twitter: @AmarantusBio .... 9,899 followers.
It's quite possible that today could be the bottom on $AMBS.
Just saying!!!
Twitter: @AmarantusBio .... 9,899 followers.
The failure to file the 10-K on time is inexcusable considering it has happened before. The one thing the company doesn't need is the distractions that such a failure creates in the market with the questions that it raises.
It's easy for Gerald to dismiss the shareholder's concerns with "flip" phrases such as "If you can't stand the heat get out of the kitchen".
Fortunately the share price won't drop any further tomorrow. Also Gerald will have a three day break to formulate a plan to recover from his latest fiasco.
Just saying!!!
Note to Gerald: Your "street cred" is on the line here.